Michele Louise Ramien
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michele Louise Ramien has a total of 243 co-authors. Here are the top co-authors by number of shared publications:
Danielle Marcoux
Division of Dermatology, Department of Pediatrics, Sainte‐Justine University Hospital Center University of Montreal Montreal Canada
7 shared publicationsIrene Lara-Corrales
Division of Dermatology, Department of Pediatrics, Hospital for Sick Children, Toronto, ON, Canada
6 shared publicationsAnnie Zhang
Sanofi Cambridge Massachusetts USA
3 shared publications- Elena Pope
Division of Dermatology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
3 shared publications Ian Landells
Division of Dermatology, Departments of Medicine and Pediatrics, Memorial University, St. John's, NL, Canada
3 shared publications- Irene Lara-Corrales
Division of Dermatology, Hospital for Sick Children University of Toronto Toronto Ontario Canada
3 shared publications
Latest Publications
- Open Access
- 12 October 2026
- Published by Wiley in Pediatric Dermatology
Interim Update on Reactive Infectious Mucocutaneous Eruption ( RIME )
Reactive infectious mucocutaneous eruption (RIME), a term describing blistering skin and mucosal lesions, is a term coined by a group of Pediatric Dermatology Research Alliance (PeDRA) researchers and first published in 2021. Since that time, the literature has grown with reports of diverse infectious triggers, management strategies, and complications. This expert opinion PeDRA perspective, developed by a group conducting a consensus process on management of RIME, is an interim update on the current state of diagnosis and management of RIME with a focus on practical information for the busy clinician.
- 12 October 2026
- Published by Wiley in Pediatric Dermatology
Open AccessInterim Update on Reactive Infectious Mucocutaneous Eruption ( RIME )
Reactive infectious mucocutaneous eruption (RIME), a term describing blistering skin and mucosal lesions, is a term coined by a group of Pediatric Dermatology Research Alliance (PeDRA) researchers and first published in 2021. Since that time, the literature has grown with reports of diverse infectious triggers, management strategies, and complications. This expert opinion PeDRA perspective, developed by a group conducting a consensus process on management of RIME, is an interim update on the current state of diagnosis and management of RIME with a focus on practical information for the busy clinician.
- 4 September 2026
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
Geographic Distribution and Rural Access to General and Pediatric Dermatology in Canada: A Cross-Sectional Geospatial Analysis
Background: In Canada, pediatric dermatology faces challenges with workforce shortages, geographic maldistribution, and limited rural access, yet national data on provider distribution are lacking. Objectives: This study aimed to visualize the geographic distribution of general and pediatric dermatologists across Canada, assess 10 year temporal changes, and examine associations between service availability, rurality, and socioeconomic deprivation. Methods: Geospatial analysis was conducted using Canadian Institute of Health Information billing data and provincial College of Physicians and Surgeons data. Dermatologists were mapped at the census subdivision (CSD) level or economic region (ER) level in Quebec. Pediatric and adolescent care were defined using billing thresholds. Spatial distribution and Canadian Index of Multiple Deprivation indicators were visualized using a geographic information system (ArcGIS). Results: Eighty-eight of 3879 CSDs nationally contained at least 1 dermatologist, including a single rural CSD. In Quebec, 15 of 17 ERs had at least 1 dermatologist, including 4 rural ERs. Pediatric and adolescent dermatology care was confined to a small number of urban CSDs, with no rural coverage. Over 10 years, growth in the general dermatology workforce was restricted to large metropolitan areas and did not translate into increased pediatric or adolescent care. Known pediatric dermatologists (n = 55) were centralized in urban academic centers, and services were disproportionately located in socioeconomically advantaged areas. Conclusion: Pediatric dermatology access is marked by urban concentration, minimal rural availability, and persistent socioeconomic inequities. General dermatology workforce expansion alone has not improved pediatric care access, highlighting the need for equity-oriented workforce planning and improved national tracking.
- 4 September 2026
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
Geographic Distribution and Rural Access to General and Pediatric Dermatology in Canada: A Cross-Sectional Geospatial Analysis
Background: In Canada, pediatric dermatology faces challenges with workforce shortages, geographic maldistribution, and limited rural access, yet national data on provider distribution are lacking. Objectives: This study aimed to visualize the geographic distribution of general and pediatric dermatologists across Canada, assess 10 year temporal changes, and examine associations between service availability, rurality, and socioeconomic deprivation. Methods: Geospatial analysis was conducted using Canadian Institute of Health Information billing data and provincial College of Physicians and Surgeons data. Dermatologists were mapped at the census subdivision (CSD) level or economic region (ER) level in Quebec. Pediatric and adolescent care were defined using billing thresholds. Spatial distribution and Canadian Index of Multiple Deprivation indicators were visualized using a geographic information system (ArcGIS). Results: Eighty-eight of 3879 CSDs nationally contained at least 1 dermatologist, including a single rural CSD. In Quebec, 15 of 17 ERs had at least 1 dermatologist, including 4 rural ERs. Pediatric and adolescent dermatology care was confined to a small number of urban CSDs, with no rural coverage. Over 10 years, growth in the general dermatology workforce was restricted to large metropolitan areas and did not translate into increased pediatric or adolescent care. Known pediatric dermatologists (n = 55) were centralized in urban academic centers, and services were disproportionately located in socioeconomically advantaged areas. Conclusion: Pediatric dermatology access is marked by urban concentration, minimal rural availability, and persistent socioeconomic inequities. General dermatology workforce expansion alone has not improved pediatric care access, highlighting the need for equity-oriented workforce planning and improved national tracking.
- Open Access
- 18 August 2026
- Published by Wiley in Pediatric Dermatology
Growth Assessment in Children Under 12 Years With Moderate‐to‐Severe Atopic Dermatitis Included in the PEDISTAD Observational Registry
Background/Objective: The multifactorial disease burden of moderate‐to‐severe atopic dermatitis (AD) may affect children's growth. We report height, weight, and body mass index (BMI) of children under 12 years old with moderate‐to‐severe AD in comparison to the general population. Methods: This was a cross‐sectional analysis of enrollment data from PEDISTAD, a global real‐world observational study of pediatric patients < 12 years old with moderate‐to‐severe AD. Results: Among the 1329 children with moderate‐to‐severe AD, 72% of male children 5 to < 12 years were below the 50th percentile for height, as were 53% of females in this age group. In contrast, the weight of children 5 to < 12 years was above the 50th percentile in 56% of males and 52% of females, resulting in above‐average BMI values. In the 0 to < 5 years old age groups, height and weight were above the 50th percentile for 59% and 50% of female children, and 52% and 42% of male children, respectively. Conclusions: This real‐world observational study showed in children 5 to < 12 years old with moderate‐to‐severe AD that the average height was lower than the US 50th percentile, with a more pronounced reduction in male children. Additionally, higher weight and, as a result, higher BMI were observed in the children included in this analysis. Trial Registration: ClinicalTrials.gov identifier: NCT03687359
- 18 August 2026
- Published by Wiley in Pediatric Dermatology
Open AccessGrowth Assessment in Children Under 12 Years With Moderate‐to‐Severe Atopic Dermatitis Included in the PEDISTAD Observational Registry
Background/Objective: The multifactorial disease burden of moderate‐to‐severe atopic dermatitis (AD) may affect children's growth. We report height, weight, and body mass index (BMI) of children under 12 years old with moderate‐to‐severe AD in comparison to the general population. Methods: This was a cross‐sectional analysis of enrollment data from PEDISTAD, a global real‐world observational study of pediatric patients < 12 years old with moderate‐to‐severe AD. Results: Among the 1329 children with moderate‐to‐severe AD, 72% of male children 5 to < 12 years were below the 50th percentile for height, as were 53% of females in this age group. In contrast, the weight of children 5 to < 12 years was above the 50th percentile in 56% of males and 52% of females, resulting in above‐average BMI values. In the 0 to < 5 years old age groups, height and weight were above the 50th percentile for 59% and 50% of female children, and 52% and 42% of male children, respectively. Conclusions: This real‐world observational study showed in children 5 to < 12 years old with moderate‐to‐severe AD that the average height was lower than the US 50th percentile, with a more pronounced reduction in male children. Additionally, higher weight and, as a result, higher BMI were observed in the children included in this analysis. Trial Registration: ClinicalTrials.gov identifier: NCT03687359
- 12 March 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (7) , 1571-1573
Beyond the Target: Re‐Emergence of Mycoplasma pneumoniae Supports Reclassification of Adult Mucocutaneous Eruptions
- 12 March 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (7) , 1571-1573
Beyond the Target: Re‐Emergence of Mycoplasma pneumoniae Supports Reclassification of Adult Mucocutaneous Eruptions
- Open Access
- 9 March 2026
- Published by Wiley in Pediatric Dermatology
- Vol. 43 (4) , 929-932
Therapy With Doxycycline and Hydroxychloroquine Enables Surgical Excision of Ulcerated Cutaneous Granulomas in a Patient With Ataxia Telangiectasia
The rubella virus vaccine strain can cause granulomas in patients with inborn errors of immunity that may evolve into chronic, recalcitrant ulcers. This report details treatment of ulcerated rubella granulomas in a patient with ataxia telangiectasia with doxycycline and hydroxychloroquine resulting in partial ulcer healing within 4 weeks, which in turn enabled surgical excision. Though this treatment did not cure or clear the rubella virus, that is known to persist in patients with inborn errors of immunity like ataxia telangiectasia, it enabled durable local lesion control of typically chronic, highly morbid ulcers. Histopathology of skin and bone lesions, the latter not previously described in the literature, is included.
- 9 March 2026
- Published by Wiley in Pediatric Dermatology
- Vol. 43 (4) , 929-932
Open AccessTherapy With Doxycycline and Hydroxychloroquine Enables Surgical Excision of Ulcerated Cutaneous Granulomas in a Patient With Ataxia Telangiectasia
The rubella virus vaccine strain can cause granulomas in patients with inborn errors of immunity that may evolve into chronic, recalcitrant ulcers. This report details treatment of ulcerated rubella granulomas in a patient with ataxia telangiectasia with doxycycline and hydroxychloroquine resulting in partial ulcer healing within 4 weeks, which in turn enabled surgical excision. Though this treatment did not cure or clear the rubella virus, that is known to persist in patients with inborn errors of immunity like ataxia telangiectasia, it enabled durable local lesion control of typically chronic, highly morbid ulcers. Histopathology of skin and bone lesions, the latter not previously described in the literature, is included.
- Open Access
- 19 September 2025
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 26 (6) , 1031-1043
Systemic Treatments in Moderate-to-Severe Atopic Dermatitis in Pediatric Patients up to 12 Years of Age: Real-World Treatment Outcomes from the PEDISTAD Registry
Background Atopic dermatitis (AD), a chronic systemic disease, can cause intense skin itching and negatively impact sleep, mood, and quality of life (QoL) for patients and families. Methods PEDISTAD is an ongoing, 10-year, observational registry describing disease characteristics, atopic comorbidities, and treatment patterns in pediatric patients (aged <12 years at enrollment) with moderate-to-severe AD. This 3-year interim analysis evaluates clinician-reported and caregiver-reported/patient-reported outcomes (Eczema Area and Severity Index [EASI], percent body surface area affected, worst itching/scratching, Children’s Dermatology Life Quality Index, and Dermatitis Family Impact) in children treated with dupilumab, methotrexate, and/or cyclosporine. Outcomes were assessed as change from therapy start to last observation (either data cutoff date or treatment discontinuation). Results Mean (±SE) EASI scores at the time of the last 3-year interim observation were consistent with mild disease in the dupilumab cohort and moderate disease in the methotrexate and cyclosporine cohorts. Improvements in pruritus were numerically greater in the dupilumab cohort relative to the methotrexate and cyclosporine cohorts, while improvements in QoL were similar in the dupilumab and methotrexate cohorts, with no significant change in the cyclosporine cohort. Rates of AD exacerbation were numerically lower with dupilumab treatment relative to methotrexate treatment which were numerically lower than cyclosporine treatment. Dupilumab discontinuation rates were numerically lower relative to methotrexate which were numerically lower than cyclosporine. Conclusions This PEDISTAD 3-year interim analysis of dupilumab, methotrexate, and cyclosporine treatment in children with AD demonstrates numerically greater improvements in AD signs, symptoms and QoL with dupilumab treatment relative to methotrexate and cyclosporine [Video abstract and graphical abstract available]. Clinical Trial Registration NCT03687359. Graphical abstract Video abstract Supplementary file1 (MP4 58163 KB)
- 19 September 2025
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 26 (6) , 1031-1043
Open AccessSystemic Treatments in Moderate-to-Severe Atopic Dermatitis in Pediatric Patients up to 12 Years of Age: Real-World Treatment Outcomes from the PEDISTAD Registry
Background Atopic dermatitis (AD), a chronic systemic disease, can cause intense skin itching and negatively impact sleep, mood, and quality of life (QoL) for patients and families. Methods PEDISTAD is an ongoing, 10-year, observational registry describing disease characteristics, atopic comorbidities, and treatment patterns in pediatric patients (aged <12 years at enrollment) with moderate-to-severe AD. This 3-year interim analysis evaluates clinician-reported and caregiver-reported/patient-reported outcomes (Eczema Area and Severity Index [EASI], percent body surface area affected, worst itching/scratching, Children’s Dermatology Life Quality Index, and Dermatitis Family Impact) in children treated with dupilumab, methotrexate, and/or cyclosporine. Outcomes were assessed as change from therapy start to last observation (either data cutoff date or treatment discontinuation). Results Mean (±SE) EASI scores at the time of the last 3-year interim observation were consistent with mild disease in the dupilumab cohort and moderate disease in the methotrexate and cyclosporine cohorts. Improvements in pruritus were numerically greater in the dupilumab cohort relative to the methotrexate and cyclosporine cohorts, while improvements in QoL were similar in the dupilumab and methotrexate cohorts, with no significant change in the cyclosporine cohort. Rates of AD exacerbation were numerically lower with dupilumab treatment relative to methotrexate treatment which were numerically lower than cyclosporine treatment. Dupilumab discontinuation rates were numerically lower relative to methotrexate which were numerically lower than cyclosporine. Conclusions This PEDISTAD 3-year interim analysis of dupilumab, methotrexate, and cyclosporine treatment in children with AD demonstrates numerically greater improvements in AD signs, symptoms and QoL with dupilumab treatment relative to methotrexate and cyclosporine [Video abstract and graphical abstract available]. Clinical Trial Registration NCT03687359. Graphical abstract Video abstract Supplementary file1 (MP4 58163 KB)
- 22 August 2025
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 44 (12) , e454-e458
Mycoplasma pneumoniae: Extrapulmonary Manifestations in Children With Focus on Mucocutaneous Disease
- 22 August 2025
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 44 (12) , e454-e458
Mycoplasma pneumoniae: Extrapulmonary Manifestations in Children With Focus on Mucocutaneous Disease
- Open Access
- 19 May 2025
- Published by Wiley in Pediatric Dermatology
- Vol. 42 (6) , 1239-1247
Peeling Skin, Leukonychia, Acral Punctate Keratoses, Cheilitis and Knuckle Pads ( PLACK ) Syndrome: An Updated Review of Cases and Identification of a Recurrent CAST Variant in Two Patients
Peeling skin, leukonychia, acral punctate keratoses, cheilitis, and knuckle pads (PLACK) syndrome (OMIM616295) is an exceptionally rare autosomal recessive genodermatosis caused by loss‐of‐function pathogenic variants in the CAST gene, encoding calpastatin. A total of 19 cases have been described in 12 articles, among families with unique de novo genetic variants of CAST. We describe two pediatric PLACK cases with a homozygous loss‐of‐function CAST variant ( c.571G>T , p.Gly191Ter) which represents the only recurrent genetic variant of PLACK syndrome reported in the literature.
- 19 May 2025
- Published by Wiley in Pediatric Dermatology
- Vol. 42 (6) , 1239-1247
Open AccessPeeling Skin, Leukonychia, Acral Punctate Keratoses, Cheilitis and Knuckle Pads ( PLACK ) Syndrome: An Updated Review of Cases and Identification of a Recurrent CAST Variant in Two Patients
Peeling skin, leukonychia, acral punctate keratoses, cheilitis, and knuckle pads (PLACK) syndrome (OMIM616295) is an exceptionally rare autosomal recessive genodermatosis caused by loss‐of‐function pathogenic variants in the CAST gene, encoding calpastatin. A total of 19 cases have been described in 12 articles, among families with unique de novo genetic variants of CAST. We describe two pediatric PLACK cases with a homozygous loss‐of‐function CAST variant ( c.571G>T , p.Gly191Ter) which represents the only recurrent genetic variant of PLACK syndrome reported in the literature.
- Open Access
- 18 March 2025
- Published by Elsevier in JID Innovations
- Vol. 5 (4) , 100363
Cutaneous and Gut Dysbiosis in Alopecia Areata: A Review
- 18 March 2025
- Published by Elsevier in JID Innovations
- Vol. 5 (4) , 100363
Open AccessCutaneous and Gut Dysbiosis in Alopecia Areata: A Review